SLC7A11 and neoplasm: Under the rubric of tumor immunity, SLC13A3 activates the NRF2-SLC7A11 pathway by taking up itaconic acid, thereby conferring resistance to ferroptosis in tumor cells and reducing the efficacy of immune checkpoint blockade (ICB) therapy.